RATIONALE AND OBJECTIVES: The aim of this prospective study was to investigate using multiparametric and multinuclear magnetic resonance imaging during preoperative systemic therapy for locally advanced breast cancer. MATERIALS AND METHODS: Women with operable stage 2 or 3 breast cancer who received preoperative systemic therapy were studied using dynamic contrast-enhanced magnetic resonance imaging, magnetic resonance spectroscopy, and ²³Na magnetic resonance. Quantitative metrics of choline peak signal-to-noise ratio, total tissue sodium concentration, tumor volumes, and Response Evaluation Criteria in Solid Tumors were determined and compared to final pathologic results using receiver-operating characteristic analysis. Hormonal markers were investigated. Statistical significance was set at P < .05. RESULTS: Eighteen eligible women were studied. Fifteen responded to therapy, four (22%) with pathologic complete response and 11 (61%) with pathologic partial response. Three patients (17%) had no response. Among estrogen receptor-positive, HER2-positive, and triple-negative phenotypes, observed frequencies of pathologic complete response, pathologic partial response, and no response were 2, 5, and 0; 1, 4, and 0; and 1, 1, and 3, respectively. Responders (pathologic complete response and pathologic partial response) had the largest reductions in choline signal-to-noise ratio (35%, from 7.2 ± 2.3 to 4.6 ± 2; P < .01) compared to nonresponders (11%, from 8.4 ± 2.7 to 7.5 ± 3.6; P = .13) after the first cycle. Total tissue sodium concentration significantly decreased in responders (27%, from 66 ± 18 to 48.4 ± 8 mmol/L; P = .01), while there was little change in nonresponders (51.7 ± 7.6 to 56.5 ± 1.6 mmol/L; P = .50). Lesion volume decreased in responders (40%, from 78 ± 78 to 46 ± 51 mm³; P = .01) and nonresponders (21%, from 100 ± 104 to 79.2 ± 87 mm³; P = .23) after the first cycle. The largest reduction in Response Evaluation Criteria in Solid Tumors occurred after the first treatment in responders (18%, from 24.5 ± 20 to 20.2 ± 18 mm; P = .01), with a slight decrease in tumor diameter noted in nonresponders (17%, from 23 ± 19 to 19.2 ± 19.1 mm; P = .80). CONCLUSIONS: Multiparametric and multinuclear imaging parameters were significantly reduced after the first cycle of preoperative systemic therapy in responders, specifically, choline signal-to-noise ratio and sodium. These new surrogate radiologic biomarkers maybe able to predict and provide a platform for potential adaptive therapy in patients.
RATIONALE AND OBJECTIVES: The aim of this prospective study was to investigate using multiparametric and multinuclear magnetic resonance imaging during preoperative systemic therapy for locally advanced breast cancer. MATERIALS AND METHODS:Women with operable stage 2 or 3 breast cancer who received preoperative systemic therapy were studied using dynamic contrast-enhanced magnetic resonance imaging, magnetic resonance spectroscopy, and ²³Na magnetic resonance. Quantitative metrics of choline peak signal-to-noise ratio, total tissue sodium concentration, tumor volumes, and Response Evaluation Criteria in Solid Tumors were determined and compared to final pathologic results using receiver-operating characteristic analysis. Hormonal markers were investigated. Statistical significance was set at P < .05. RESULTS: Eighteen eligible women were studied. Fifteen responded to therapy, four (22%) with pathologic complete response and 11 (61%) with pathologic partial response. Three patients (17%) had no response. Among estrogen receptor-positive, HER2-positive, and triple-negative phenotypes, observed frequencies of pathologic complete response, pathologic partial response, and no response were 2, 5, and 0; 1, 4, and 0; and 1, 1, and 3, respectively. Responders (pathologic complete response and pathologic partial response) had the largest reductions in choline signal-to-noise ratio (35%, from 7.2 ± 2.3 to 4.6 ± 2; P < .01) compared to nonresponders (11%, from 8.4 ± 2.7 to 7.5 ± 3.6; P = .13) after the first cycle. Total tissue sodium concentration significantly decreased in responders (27%, from 66 ± 18 to 48.4 ± 8 mmol/L; P = .01), while there was little change in nonresponders (51.7 ± 7.6 to 56.5 ± 1.6 mmol/L; P = .50). Lesion volume decreased in responders (40%, from 78 ± 78 to 46 ± 51 mm³; P = .01) and nonresponders (21%, from 100 ± 104 to 79.2 ± 87 mm³; P = .23) after the first cycle. The largest reduction in Response Evaluation Criteria in Solid Tumors occurred after the first treatment in responders (18%, from 24.5 ± 20 to 20.2 ± 18 mm; P = .01), with a slight decrease in tumor diameter noted in nonresponders (17%, from 23 ± 19 to 19.2 ± 19.1 mm; P = .80). CONCLUSIONS: Multiparametric and multinuclear imaging parameters were significantly reduced after the first cycle of preoperative systemic therapy in responders, specifically, choline signal-to-noise ratio and sodium. These new surrogate radiologic biomarkers maybe able to predict and provide a platform for potential adaptive therapy in patients.
Authors: Antonio C Wolff; Donald Berry; Lisa A Carey; Marco Colleoni; Mitchell Dowsett; Matthew Ellis; Judy E Garber; David Mankoff; Soonmyung Paik; Lajos Pusztai; Mary Lou Smith; JoAnne Zujewski Journal: J Clin Oncol Date: 2008-02-10 Impact factor: 44.544
Authors: R P Kline; E X Wu; D P Petrylak; M Szabolcs; P O Alderson; M L Weisfeldt; P Cannon; J Katz Journal: Clin Cancer Res Date: 2000-06 Impact factor: 12.531
Authors: Riham H Ei Khouli; Michael A Jacobs; Sarah D Mezban; Peng Huang; Ihab R Kamel; Katarzyna J Macura; David A Bluemke Journal: Radiology Date: 2010-07 Impact factor: 11.105
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Andriy M Babsky; Stephen Topper; Hong Zhang; Yong Gao; Judy R James; Shahryar K Hekmatyar; Navin Bansal Journal: Magn Reson Med Date: 2008-03 Impact factor: 4.668
Authors: Michael A Jacobs; Ronald Ouwerkerk; Ihab Kamel; Paul A Bottomley; David A Bluemke; Hyun S Kim Journal: J Magn Reson Imaging Date: 2009-03 Impact factor: 5.119
Authors: Michael A Jacobs; Antonio C Wolff; Katarzyna J Macura; Vered Stearns; Ronald Ouwerkerk; Riham El Khouli; David A Bluemke; Richard Wahl Journal: J Natl Cancer Inst Monogr Date: 2015-05
Authors: Ahmed A Haruoni; Jakir Hossain; Riham El Khouli; Kant M Matsuda; David A Bluemke; Nael F Osman; Michael A Jacobs Journal: Med Phys Date: 2012-12 Impact factor: 4.071
Authors: Patrick J Bolan; Eunhee Kim; Benjamin A Herman; Gillian M Newstead; Mark A Rosen; Mitchell D Schnall; Etta D Pisano; Paul T Weatherall; Elizabeth A Morris; Constance D Lehman; Michael Garwood; Michael T Nelson; Douglas Yee; Sandra M Polin; Laura J Esserman; Constantine A Gatsonis; Gregory J Metzger; David C Newitt; Savannah C Partridge; Nola M Hylton Journal: J Magn Reson Imaging Date: 2016-12-16 Impact factor: 4.813